Indee Labs

Indee Labs

Indee Labs focuses on the development of microfluidic vortex shedding for rapidly and efficiently transfecting human primary immune cells with negligible perturbation. The team is focused on developing its core technology for short turnaround chimeric antigen receptor T cell (CAR-T) development and manufacturing.

Edit ID  5312607 

Ryan Pawell"Bringing all online material inline with funding announcements to avoid confusion during PR."
Ryan Pawell edited on 16 May, 2018
Edits made to:
Article (+129/-255 characters)

As of AprilMay 20172018, Indee Labs had accumulated more than USD$4.45.4 million dollars in angel, venture and non-dilutive capital.


In FebruaryJuly 20162017, Indee Labs closed USD$550K1.3M in accelerator and angel financing from IndieBioJude Gomila, Shaun Maguire and SOSVY Combinator among others.


In March ofMay 20172018, Indee Labs kickedclosed offout a seed round resulting in USD$3M2.6M in angel and venture financing from JudeFounders GomilaFund, Shaun Maguire,Main YSequence CombinatorVentures, Social+Capital, Main Sequence Ventures and Founders Fundalso among others inclusive of refunds under an Overseas Finding for Australia's R&D Tax Incentive.


Funding Agency

Overseas Finding


43.5% of eligible R&D expenditureAUD$502,050


Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.